FDA approves Bristol Myers’ Onureg as continued treatment for AML
The FDA approval is based on results from the Phase 3 QUAZAR AML-001 clinical trial, an international, randomised,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
02 Sep 20
The FDA approval is based on results from the Phase 3 QUAZAR AML-001 clinical trial, an international, randomised,…
02 Sep 20
JTX-1811 is a monoclonal antibody, designed to selectively target immunosuppressive tumor-infiltrating T regulatory (TITR) cells
01 Sep 20
The Phase III D8110C00001 trial will evaluate the safety, efficacy and immunogenicity of the AZD1222 vaccine in up…
31 Aug 20
Farxiga is the first medicine to significantly prolong survival in a renal outcomes trial in patients with chronic…
31 Aug 20
The EUA expands Veklury’s previous authorisation to treat hospitalised patients with Covid-19 regardless of oxygen status
28 Aug 20
IMO is a rare, severe autosomal recessive disorder is caused due to mutations in the TCIRG1 gene, which…
27 Aug 20
The EC regulatory approval for BLENREP is supported by data from the pivotal DRiving Excellence in Approaches to…
26 Aug 20
As part of the agreement, Takeda and Engitix will complete validation and preclinical development of new therapeutics for…
26 Aug 20
Sinovac will provide Bio Farma with bulk vaccine, enabling it manufacture a minimum of 40 million doses of…
25 Aug 20
Forbius develops a portfolio of selective potent inhibitors of TGF-beta 1 & 3, which mediate immunosuppression and fibrosis